Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin. 2014 Feb;32(2):70-5. doi: 10.1016/j.eimc.2013.02.009
Smets E, Brogan AJ, Hill A, Adriaenssen I, Sawyer AW, Domingo-Pedrol P, Gostkorzewicz J, Ledesma F. Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain. Enferm Infecc Microbiol Clin. 2013 Aug;31(7):430-6.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Wilburn J, Crawford SR, McKenna SP, Twiss J, Ben-L'amri M, Kemp K, Campbell S. Assessing patient reported outcome in Crohn's disease. Poster presented at the 2012 Digestive Disorders Federation Meeting; June 2012. Liverpool. [abstract] Gut. 2012; 61(Suppl 2):391. doi: 10.1136/gutjnl-2012-302514d.229
Serna MC, Real J, Ribes E, Marsal JR, Godoy P, Galvin L. Factors determining antibiotic prescription in primary care. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):193-200. doi: 10.1016/j.eimc.2010.09.012
Anthony M, Clarkson TB. Association between plasma isoflavone and plasma lipoprotein concentrations. J. Med. Food. 1999;2(3-4):263-6.
Vakil N, McSorley DJ. Reflux symptoms after h. pylori treatment in duodenal ulcer. Poster presented at the British Society of Gastroenterology Diamond Jubilee Meeting; March 1997. [abstract] Gut. 1997 Jan; 40(Suppl 1):A128.
Brullet E, Campo R, Calvet X, Coroleu D, Rivero E, Simó Deu J. Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut. 1996 Aug;39(2):155-8. doi: 10.1136/gut.39.2.155